SITE015-0260

SITE015 (POL) › SITE015-0260

SITE015-0260

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2026-07-04

enrolled

AEs

1

Serious

0

Dropout signal

–

Adverse events

1

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-04 (study day 56); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.